{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "EPC",
  "name": "Edgewell Personal Care Company",
  "url": "https://orbyd.app/dossiers/EPC/",
  "json_url": "https://orbyd.app/dossiers/EPC.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Take-private special situation: the board rejected Yellow Wood's $30 bid as too low, and mid-July sell-side PT raises (Canaccord $34, Wells Fargo $30) confirm a >$30 intrinsic read. But a month on no competing bid has surfaced, the theme is maturing, and the ~2026-08-03 Q3 print is the next binary — front-running is over, this is now a waiting game near 52-week highs.",
  "invalidation_trigger": "A weekly close below $24 confirms the takeover premium has fully bled with no competing bid, reverting EPC to standalone value where organic sales remain negative and price sits back beneath the pre-bid consolidation shelf near $23.",
  "catalyst_date": "2026-08-03",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "consumer-discretionary-rotation"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Standalone floor: pre-bid ~$23.11 (2026-06-18). A full premium bleed reverts here, into value-trap territory (Q2 organic -2.4%, adj EBITDA $73.8M vs $84.7M).",
    "Earnings blackout: Q3 FY2026 print estimated ~2026-08-03 before open (quarter ended 2026-06-30) — first hard standalone read on the H2 organic ramp and summer sun-care sell-through; avoid fresh entries into an unconfirmed date.",
    "Turnaround mechanics: Feminine Care sold to Essity for ~$340M cash (closed 2026-02-02, now discontinued ops); adj net leverage ~4.0x at Q2 targeted to 3.3-3.5x by FY-end. FY2026 guide (reaffirmed 2026-05-06): organic -1.0% to +2.0%, adj EPS $1.70-2.10, adj EBITDA $245-265M, adj FCF $80-110M; back-half weighted. Restructuring charges raised to ~$90M from $65M.",
    "M&A situation (2026-06-22): Yellow Wood Partners tabled an unsolicited $30/share take-private bid; board rejected outright as too low (no counter), signaling a >$30 intrinsic view. Yellow Wood owns Chapstick, Noxzema, Dr. Scholl's. No agreed deal exists — watch for a sweetened/competing bid or a formal process.",
    "Sell-side caught up post-event, mixed ratings: Canaccord Buy PT $34 (2026-07-07), Wells Fargo Overweight $30 (2026-07-08), UBS Neutral $29 (2026-07-16), Barclays Equal-Weight $28 (2026-07-21). PT catch-up to the event, not a fundamental upgrade cycle.",
    "Standalone value-trap risk: Q2 organic -2.4% (Wet Shave NA -6.0%, Sun Care -8.4%), adj EBITDA $73.8M vs $84.7M. FY2026 organic guide -1.0% to +2.0%, back-half weighted; restructuring raised to ~$90M from $65M.",
    "Turnaround mechanics: Feminine Care sold to Essity for ~$340M cash (closed 2026-02-02, now discontinued ops). Adj net leverage ~4.0x at Q2, targeted 3.3–3.5x by FY-end; ~$85M buyback authorization remaining; dividend $0.15/qtr paid 2026-07-09.",
    "Price structure: gapped +18% 2026-06-23, 52-week high $28.01 (2026-07-03), consolidating high-$20s below the rejected-bid $30 anchor and above the pre-bid ~$23.11 shelf (2026-06-18). Added to Russell 2000 Dynamic Index 2026-06-27 (mechanical flow overlap). Theme flipped to MATURING (consumer-discretionary-rotation)."
  ],
  "body_markdown": "## Current Thesis\nThe leg on offer is take-private M&A follow-through, not the organic turnaround. Yellow Wood Partners' unsolicited $30/share bid (2026-06-22) was rejected outright — no counter — a board signal that intrinsic value sits above $30. Since then the sell-side has caught up rather than led: Canaccord Buy PT $34 (2026-07-07), Wells Fargo Overweight $30 (2026-07-08), UBS Neutral $29 (2026-07-16), Barclays Equal-Weight $28 (2026-07-21). That price-target cluster re-rated the whole coverage list toward and above the rejected bid inside two weeks. The problem for a momentum frame is timing: it is a month since the pop, no competing bidder or formal process has appeared, and the theme (consumer-discretionary-rotation) has flipped to maturing. The ~2026-08-03 Q3 print is the next binary and lands before any M&A resolution. This is a special-situation waiting game trading near a 52-week high on speculation, not an accelerating narrative front-running the tape.\n\n## Bull Case\n- Yellow Wood's $30/share bid (2026-06-22) was refused outright, not negotiated — a board stance that intrinsic value clears $30. The sponsor's consumer-brand pedigree (Chapstick, Noxzema, Dr. Scholl's) lends credibility to a sweetened or competing approach.\n- Sell-side re-rated toward the deal within two weeks: Canaccord $34 (2026-07-07), Wells Fargo $30 (2026-07-08), UBS $29 (2026-07-16), Barclays $28 (2026-07-21). The top of that range now prints above the rejected bid.\n- Clean carve-up target post-divestiture: Feminine Care sold to Essity for ~$340M cash (closed 2026-02-02, now discontinued ops), leaving Schick/Wilkinson Sword Wet Shave, Banana Boat/Hawaiian Tropic Sun Care, and Cremo/Billie/Bulldog as separately financeable brand assets.\n- Q2 FY2026 (reported 2026-05-06) adjusted EPS of $0.60 beat ~$0.44 consensus, Grooming +6.3%, management \"ahead of internal expectations\" — a firmer operating read strengthens the board's hand to hold out.\n- Deleveraging is live: adjusted net leverage ~4.0x at the Q2 balance date, targeted to 3.3–3.5x by FY-end, ~$85M buyback authorization remaining, $0.15/quarter dividend paid 2026-07-09.\n\n## Bear Case\n- A rejected offer is not a deal. A month on (2026-06-22 → 2026-07-25) no competing bid or formal process has surfaced; the ~18% event premium reverts toward the pre-bid shelf ~$23.11 (2026-06-18) if the M&A angle goes quiet.\n- Standalone fundamentals never moved with the bid: Q2 organic net sales -2.4% (Wet Shave NA -6.0%, Sun Care -8.4%), adjusted EBITDA down to $73.8M from $84.7M.\n- FY2026 organic guide (reaffirmed 2026-05-06) still spans down to -1.0% and is explicitly back-half weighted; restructuring charges were raised to ~$90M from $65M.\n- The analyst cluster stayed mixed — two of the four PT raises carry Neutral/Equal-Weight ratings. Targets rose; conviction didn't. That is price-target catch-up to an event, not a fundamental upgrade cycle.\n- Buying at a 52-week high ($28.01, 2026-07-03) on single-event speculation caps upside near a $30–34 clearing zone against a full round-trip of the pop on a \"no second bidder\" outcome.\n- The Q3 print (~2026-08-03) is a binary standalone read that could undercut the \">$30 intrinsic\" narrative if the H2 ramp and summer sun-care sell-through disappoint — and it lands before any deal clarity.\n\n## Setup & Price Structure\nShares gapped ~18% on 2026-06-23 and printed a 52-week high of $28.01 on 2026-07-03, then consolidated sideways in the high-$20s while sell-side PTs migrated up around them. Price sits below the rejected-bid $30 anchor but above the pre-bid consolidation near $23.11, and above most published targets until Canaccord's $34 outlier. Addition to the Russell 2000 Dynamic Index (2026-06-27) added a mechanical flow tailwind overlapping the event pop. A month of range-bound trade under $30 says the premium is holding but not building — the market is pricing \"waiting for the next move,\" not chasing. Against standalone value the name is stretched; against the M&A anchor it is not. The tell that the special situation has failed is a break of the event base: a weekly close below $24 puts price back beneath the pre-bid shelf with the premium gone.\n\n## Catalyst Calendar (next 30 days)\n\n- ~2026-08-03 (est.), before open — Q3 FY2026 earnings (quarter ended 2026-06-30). First hard standalone read on the H2 organic ramp and summer sun-care sell-through; binary for the \">$30 intrinsic\" case.\n- Open-ended / headline-driven — any Yellow Wood sweetened bid, competing bidder, or formal sale-process announcement. No scheduled date; the M&A clock is the swing factor and could fire any session.\n\n## Elapsed catalysts\n\n- Passed: $0.15/quarter dividend paid 2026-07-09 (ex-date already elapsed; no income catalyst in the window). *(passed 24d ago)*\n\n## What Would Change Our Mind\n- A competing or sweetened offer at ≥$32, or a formal sale-process announcement, would flip the read from stalled speculation to a live auction and justify pressing the name through the maturing-theme flag.\n- A weekly close below $24 would confirm the takeover premium has bled out with no second bidder, reverting the frame to standalone value where organic sales are still negative.\n- The Q3 print is the swing: an organic return to positive growth would validate the standalone case independent of any deal; another -2%-and-worse organic quarter leaves only the rejected bid holding the price up. Best practice into an unresolved M&A situation with a binary print six-to-seven sessions out is to stand aside until the print clears or a second bidder appears.\n\n## Correlation Notes\n- Theme: consumer-discretionary-rotation, now maturing — moves with the small-cap consumer-brand rotation basket, decoupled from the AI/semiconductor complex.\n- Idiosyncratic M&A beta: price action is deal-headline-driven, so realized correlation to the broad tape runs low during the event window; index moves matter less than any Yellow Wood follow-up.\n- Sponsor read-through: Yellow Wood's existing consumer portfolio (Chapstick, Noxzema, Dr. Scholl's) is the relevant comp set for how it might structure and finance an Edgewell take-private.\n- Small-cap index linkage: Russell 2000 Dynamic Index membership (added 2026-06-27) ties a slice of flow to small-cap index rebalancing rather than fundamentals.\n- Seasonality: Sun Care sell-through (Banana Boat/Hawaiian Tropic) is the Q3 swing variable, correlated to summer weather and retail traffic more than to macro.",
  "first_seen": "2026-06-18",
  "last_analyzed": "2026-07-25T08:26:24+00:00",
  "last_synthesized": "2026-07-25",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}